New Clinical Trials Now Recruiting For VX-680 For T315I Mutation

Clinical trials are now recruiting patients for the new Merck drug VX-680 which has been developed to work on the T315I mutation. There are 3 separate trials that are now open with trial locations in Texas, Massachusetts, New Jersey, Pennsylvania, and Wisconsin. CML patients who have failed on Gleevec, AMN107, and BMS354825 may be eligible for this trial. This is a potentially a very important drug for CML patients because it may work on the T315I mutation. If you know of any CML patients with the T315I mutation let them know about these trial locations so can find out if they may be eligible.